Ba Khadija, Salle Laurence, Serhal Laudy, Sow Mamadou Adama, Magne Julien, Lacroix Philippe, Chastaingt Lucie, Aboyans Victor
Inserm 1094 & IRD270, Limoges University Hospital, Limoges, France.
Inserm 1094 & IRD270, Limoges University Hospital, Limoges, France; Department of Endocrinology, Diabetology and Metabolism, Dupuytren University Hospital, Limoges, France.
Diabetes Metab. 2024 Nov;50(6):101582. doi: 10.1016/j.diabet.2024.101582. Epub 2024 Oct 3.
In patients with type-2 diabetes mellitus (T2DM), sodium-glucose co-transporter 2 inhibitors are suspected to increase the risk of amputation. "Traditional" diuretics may increase major adverse limb events (MALEs), but the evidence is weak. We studied the association between common diuretics (i.e. thiazides, loop- and potassium-sparing diuretics) and MALEs/amputations in patients with T2DM.
Consecutive T2DM patients without cardiovascular history referred to our center for cardiovascular check-ups were retrospectively studied. Follow-up data on MALEs were collected. We used Cox models to assess the association between diuretics and MALEs, or amputation alone. A propensity score with inverse probability of diuretic treatment weighting (IPTW) analysis was performed.
We studied 1309 patients, (59.5 ± 10.7 years, 51 % females) with diabetes duration of 9.1 ± 8.5 years, among whom 402 (30 %) were taking diuretics. During a follow-up of 3.8 ± 1.64 years, 121 (9.1 %) had MALEs, including 19 (1.4 %) amputations. Death occurred in 111 patients and the proportion of death was significantly different between groups: patients with diuretics n = 49, 44.1% vs patients without diuretics n = 62, 55.9 %, P = 0.001. Diuretics, in multivariable analysis, were associated with MALEs (aHR[95 %CI] 1.96[1.32;2.91] P = 0.001), even after adjustment on propensity score (aHR 1.66[1.08;2.56] P = 0.02) and IPTW analysis (aHR 1.76[1.67;1.84] P < 0.0001). This risk was particularly increased in case of an abnormal ankle-brachial index (aHR 2.29[1.32;3.96], P = 0.003) at baseline. Looking at diuretic classes separately, the adjusted risk was increased with loop diuretics (aHR 2.56[1.16;5.64] P = 0.020), thiazides (aHR 2.21[1.37;3.57] P = 0.001) or potassium sparing diuretics (aHR 2.56[1.16;5.64] P = 0.020).
Diuretic treatment weighting may be associated with increased risk of MALEs. We identified several markers of increased risk of limb events where the use of diuretics should be considered with caution.
在2型糖尿病(T2DM)患者中,怀疑钠-葡萄糖协同转运蛋白2抑制剂会增加截肢风险。“传统”利尿剂可能会增加主要肢体不良事件(MALE),但证据不足。我们研究了常用利尿剂(即噻嗪类、袢利尿剂和保钾利尿剂)与T2DM患者MALE/截肢之间的关联。
对连续转诊至我们中心进行心血管检查且无心血管病史的T2DM患者进行回顾性研究。收集有关MALE的随访数据。我们使用Cox模型评估利尿剂与MALE或单独截肢之间的关联。进行了倾向评分与利尿剂治疗加权逆概率(IPTW)分析。
我们研究了1309例患者(年龄59.5±10.7岁,51%为女性),糖尿病病程9.1±8.5年,其中402例(30%)正在服用利尿剂。在3.8±1.64年的随访期间,121例(9.1%)发生了MALE,包括19例(1.4%)截肢。111例患者死亡,两组之间的死亡比例有显著差异:服用利尿剂的患者n = 49,44.1%,未服用利尿剂的患者n = 62,55.9%,P = 0.001。在多变量分析中,利尿剂与MALE相关(调整后风险比[aHR][95%置信区间]为1.96[1.32;2.91],P = 0.001),即使在调整倾向评分后(aHR为1.66[1.08;2.56],P = 0.02)和IPTW分析后(aHR为1.76[1.67;1.84],P < 0.0001)也是如此。在基线时踝臂指数异常的情况下,这种风险尤其增加(aHR为2.29[1.32;3.96],P = 0.003)。分别查看利尿剂类别,使用袢利尿剂(aHR为2.56[1.16;5.64],P = 0.020)、噻嗪类(aHR为2.21[1.37;3.57],P = 0.001)或保钾利尿剂(aHR为2.56[1.16;5.64],P = 0.020)时调整后的风险增加。
利尿剂治疗加权可能与MALE风险增加有关。我们确定了几个肢体事件风险增加的标志物,在这些情况下应谨慎考虑使用利尿剂。